About ZemairaAbout ZemairaEffective TherapyHigh PurityConvenienceWell ToleratedWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

What to expect

You expect that Alpha-1 will change your life. . .

Alpha1-proteinase inhibitor (A1-PI) deficiency—or Alpha-1—is a hereditary condition that increases the risk of emphysema.1 Once diagnosed with emphysema as a result of the condition, adults with Alpha-1 face progressive loss of lung function that can significantly impact everyday life and life expectancy.

We created Zemaira® for chronic A1-PI augmentation (Alpha-1) therapy in adult Alpha-1 patients with emphysema. Zemaira® has been shown to be safe and effective, with half or less the infusion volume and time of other Alpha-1 therapies.2-4* What’s more, Zemaira® is backed by patient programs that provide you with peace of mind.

. . .with Zemaira®, you can expect high purity, efficacy, safety, and convenience.

 
*Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.08 mL/kg/min.
Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.

Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. Eriksson S. Studies in α1-antitrypsin deficiency. ACTA Med Scand Suppl. 1965;432:1-85.
  2. Prolastin® Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, March 2003.
  3. Aralast™ Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, January 2003.
  4. Data on file, CSL Behring LLC.